CBIS almost maxed out A/S. They are diluting shares to cover FDA approval and operating expenses. There are two ways now. First increased the A/S from 850M to 1B or make another R/S and diluted again rest of the A/S Who is loosing here? Investors.
New appointment Richard Ogden is another financial burden on investors. I believe CBIS will give Richard 100M shares. A/S maxed out. CBIS issued misleading PR because PR is only talking about Richards history and appointment in CBIS but PR didn't mentioned the Richard working term I mean How many Shares CBIS is offer to work in CBIS. Big things are hiding here. IMO
News 
Market Data 
Discover 
